Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers at UT Southwestern Medical Center have discovered that CDK4/6 inhibitors alter the metabolism of pancreatic cancer cells, revealing a biologic vulnerability. By targeting altered tumor metabolism with other drugs, it may be possible to positively impact cancer treatment.
The Damon Runyon Cancer Research Foundation awarded over $4.39M to 23 researchers conducting innovative cancer research, including four Breakthrough Scientists awards. These grants aim to support novel ideas and therapies in basic and translational cancer research.
Scientists at Sanford Burnham Prebys Medical Discovery Institute have solved the atomic structure of a unique ubiquitin ligase complex, which plays a key role in modulating the immune system. The study reveals significant therapeutic potential for developing novel drug targets for cancer and inflammatory diseases.
The University of Chicago Medicine will receive a $5 million donation from the Hospira Foundation to create the Hospira Foundation Professorship in Oncology. This professorship will support research aimed at discovering new therapies and treatments for cancer.
A new study suggests that combining PARP inhibitors with c-MET inhibitors may improve treatment outcomes for patients with breast cancer and high c-MET expression levels.
Researchers identified DDA as a potent tumor suppressor metabolite derived from cholesterol and histamine cross-metabolization. Its discovery reveals a new metabolic pathway in mammals, potentially leading to the development of novel anticancer therapies.
Researchers at UNC-Chapel Hill have created a new cancer treatment that uses immune bubbles to deliver chemotherapy directly to tumors. This innovative approach reduces the need for high doses of chemotherapy, potentially leading to more effective treatment with fewer and milder side effects.
Researchers have discovered a way to light up a common cancer drug, allowing them to see where the chemo goes and how long it takes to get there. This breakthrough could lead to more personalized medicine and better understanding of how cells interact with drugs.
A recent study suggests new potential drug targets and combinations for treating breast cancer, including signaling proteins and proteins that regulate cell growth pathways. The research identifies candidate genes essential to cancer cell survival and validates a gene as a target for further study.
Changes in childhood cancer treatment and follow-up care have reduced deaths from late effects and extended lives of long-term survivors. Better screening guidelines and reduced radiation therapy have contributed to the decline in deaths.
Seven scientists with novel approaches to fighting cancer have been named recipients of the Damon Runyon-Rachleff Innovation Award. The grant funds cancer research by exceptionally creative thinkers with 'high-risk/high-reward' ideas, aiming to significantly impact cancer prevention, diagnosis, and treatment.
A recent US study found that minority and ethnic groups are being diagnosed with colorectal cancer at younger ages than non-Hispanic whites. The study reveals that these groups have twice the risk of developing the disease before age 50, with advanced stages at diagnosis.
Researchers from the Repurposing Drugs in Oncology project have found that diclofenac, a common painkiller, has significant anti-cancer properties. The study suggests that existing non-cancer drugs may represent a valuable source of novel therapies for cancer treatment.
A new study reveals that docetaxel retains effectiveness in patients with castration-resistant metastatic prostate cancer (mCRPC) treated with abiraterone. Following abiraterone, 40% of patients experienced a 50% reduction in prostate-specific antigen (PSA), demonstrating the activity of this drug sequencing.
Researchers found that auranofin reduces the survival rates of ovarian cancer cells with depleted BRCA1 levels, increasing their sensitivity to the drug. This suggests auranofin's potential as a clinical treatment for ovarian cancers with BRCA1 deficiency.
A recent study published in Cell Reports reveals that a group of protein kinases, specifically PKN2, play an essential role in congenital birth defects such as spina bifida. The researchers also found that these kinases may be potential cancer drug targets, particularly for pancreatic and breast cancers.
Researchers at The Wistar Institute used patient-derived xenograft (PDX) mouse models to test a combination of targeted therapies against relapsed melanoma. A MET inhibitor called capmatinib, when combined with BRAF and MEK inhibitors, showed significant tumor regression in all animals, suggesting a possible new mechanism of resistance.
Researchers at the University of Sheffield discovered that dasatinib can switch off signals in a protein implicated in Duchenne Muscular Dystrophy, leading to a 40% improvement in zebrafish with the condition. The drug has potential as a treatment for slowing muscle deterioration and improving symptoms in patients.
A recent study published in PLOS ONE found that statins increased overall survival among late-stage SCLC patients, while other medications showed no benefit. Radiotherapy was also identified as an independent predictor of survival.
A new injectable agent, LUM015, has been tested in a trial and found to identify cancerous tissue in human patients without adverse effects. The technology could significantly change the treatment of sarcoma by allowing surgeons to remove 100% of the tumor on the first attempt.
Researchers at the Children's Hospital of Philadelphia have identified a powerful new drug with unparalleled strength against forms of neuroblastoma that resist crizotinib. The study found that PF-06463922 showed more profound inhibition of ALK than crizotinib, leading to rapid and sustained regression in animal models.
A new study finds that Medicaid programs provide inadequate help for smoking cessation, with 10% of smokers receiving anti-smoking medication. States vary in their efforts to support smokers, with some providing more access than others.
The canSAR database has been upgraded with 3D protein structures and maps of cancer communication networks, allowing scientists to design new treatments more effectively. The updated database will enable researchers to identify key targets for future cancer drug discovery and develop innovative drugs more rapidly.
Researchers have discovered a triple therapy approach that could make treatment-resistant lung cancers susceptible to therapy. The combination of two experimental drugs and radiation therapy was found to be effective in mice with KRAS-related gene mutations.
A new study by Sylvester researchers describes the immune system's response to tumor development, highlighting the stimulator of interferon genes (STING) signaling pathway's potential suppression of colorectal cancer. Impaired STING responses may enable damaged cells to evade the immune system.
The new oral drug Palbociclib has shown promise in combating various types of cancer beyond breast cancer, including lymphoma, sarcoma, and teratoma. Early trials have demonstrated its effectiveness in slowing tumor growth and improving survival rates in patients with these conditions.
Researchers have identified NORAD, a long noncoding RNA, as crucial in maintaining proper chromosome numbers. Absence of NORAD leads to genomic instability and cells losing or gaining whole chromosomes.
Researchers discovered a novel mechanism of resistance and re-sensitization to first-generation ALK inhibitors in a patient with metastatic non-small-cell lung cancer. The study highlights the importance of repeat biopsies and molecular profiling to uncover novel resistance mechanisms.
Researchers have developed a computer model that applies social network analysis techniques to identify new ways of treating cancer. The model maps the interactions between cancer-causing proteins, predicting which ones will be most effectively targeted with drugs.
A study found that NSAIDs and opiates had no significant difference in pain scores, but NSAID use was associated with more rescue medication. Smaller chest tubes reduced pain, but efficacy has not been proven.
Mutations in follicular lymphoma have revealed new molecular targets for potential treatments, according to researchers at Queen Mary University of London. The mutations identified allow tumours to evade normal restrictions on growth, making existing therapies less effective.
A new system, TCRN, facilitates data and biospecimen sharing among cancer centers to speed up cancer research findings. This federated network uses advanced text processing technology to promote translational research across all cancer centers.
Researchers have found a class of drugs, histone deacetylase inhibitors, can eliminate kidney toxicity caused by cisplatin, a widely used chemotherapy agent. The combination therapy shows promise in reducing inflammation and cell death in the kidneys.
New research reveals that current genome analysis approaches miss detecting complex cancer mutations in well-known genes that could be targeted by existing drugs. The developed software tool, Pindel-C, identifies a large number of such events in critical cancer genes.
Researchers have found that tumors driven by IDH1 mutations are vulnerable to depletion of metabolite NAD+, which supports the development of new treatments. Inhibiting NAD+ levels can induce the death of IDH1-mutant tumor cells and inhibit tumor growth in animal models.
Researchers at VCU Massey Cancer Center describe how p53 gene mutations activate mTORC1, leading to abnormal cell proliferation. The study identifies a potential target for existing drug pemetrexed, which may have greater clinical utility against cancers with p53 dysfunction.
A new study found that experimental drugs changing energy supply in cells can halt tumor growth and extend survival in mice with cancers linked to IDH1 gene mutations. The research team discovered that cancer cells with low levels of a critical metabolic chemical, NAD, are more susceptible to these drugs.
The authors propose that lethal drugs' physical consequences should be listed as immediate cause of death and underlying condition as preceding antecedent cause. Harmonization with vital statistics registrars is crucial for consistency across provinces and territories.
A clinical trial found that anastrozole is as effective as tamoxifen in treating ductal carcinoma in situ (DCIS), a very early form of breast cancer. Anastrozole offers a new treatment option for post-menopausal women with fewer side effects, such as womb and ovarian cancers.
Researchers found similar outcomes for disease recurrence between women taking anastrozole and those taking tamoxifen, but noted significant differences in side effects. Women on anastrozole had fewer endometrial and ovarian cancers, while those on tamoxifen experienced more major thromboembolic events.
A study of postmenopausal women with DCIS found that anastrozole and tamoxifen caused different symptom profiles. Hot flashes were more common in the tamoxifen group, while musculoskeletal complaints and vaginal problems were more prevalent in those receiving anastrozole.
A single dose of psilocybin significantly decreases anxiety and depression in cancer patients, with positive effects lasting up to 6 months. The study suggests that psilocybin may be a sufficient treatment for mood disturbances in cancer patients.
Scientists at Princess Margaret Cancer Centre discovered that blocking the master regulator of bone renewal, RANKL, stops osteosarcoma. The findings provide a strong rationale for using this drug to develop targeted therapy for patients.
Researchers at Oregon State University have developed a three-drug delivery system that targets cancer cells in the lymph nodes, reducing toxicity and resistance. The technology has shown success in laboratory animals and holds potential for treating various types of cancer that spread through the lymphatic system.
A gold standard data record has been established to improve cancer genome analysis and detect somatic mutations reliably. The record, obtained from interlaboratory testing, provides a basis for laboratories to evaluate their bioinformatic methods and thresholds for detecting specific mutations.
A study of over 21,000 women found that only 1 in 6 with increased breast cancer risk take preventive medication, despite being eligible for clinical trials. Most women who started the medication continued taking it for at least a year, but usage declined over time.
Patients who discontinued ibrutinib or idelalisib due to side effects experienced durable responses after switching to another kinase inhibitor, with a 50% objective response rate and 11.9-month median progression-free survival.
A phase I/II clinical trial found that acalabrutinib promotes high response rates and durable results in patients with relapsed chronic lymphocytic leukemia while producing minimal side effects. The drug's selective blockade of the BTK pathway may offer improved tolerability compared to other treatments.
Researchers have developed a novel method to reposition an FDA-approved anti-cancer compound for targeting liver cancer tumors. The 'triple attack' technique uses nanobubbles filled with the drug to specifically target cancer cells, minimizing harm to healthy tissue.
A team of researchers discovered non-coding RNA molecules in cancer cells that stimulate an immune response by mimicking pathogens. The findings suggest these molecules may play a significant role in mediating immune responses against cancer.
A mindfulness-based stress reduction program has been shown to improve attention and reduce mistakes on difficult cognitive tasks in breast and colorectal cancer survivors. The program, known as MBSR, provides a creative solution for managing cancer-related cognitive impairment, which can be incapacitating.
The Target Validation Platform provides a single, robust infrastructure that integrates high-level information from key sources of evidence. It enables communities to work together, making the hand-off from basic research to drug discovery smoother, and is expected to grow substantially as it integrates experimental project data.
A study of 87 CLL patients found 12 genetic mutations that can be targeted by therapies already available for other cancers, including PARP and BRAF inhibitors. These mutations were detected through next-generation sequencing and may offer new treatment options for patients who fail current therapies.
A multi-center study found ibrutinib to be more effective than chlorambucil in treating CLL, with a 97.8% overall survival rate after two years compared to 85.3%. Ibrutinib also improves hemoglobin and platelet levels.
A SWOG trial shows that adding bortezomib to lenalidomide and dexamethasone therapy in early treatment improves remission time and life expectancy for myeloma patients by about a year, compared to the standard two-drug regime.
Scientists create virtual tumors to test drug treatments, achieving an 85-86% correlation with lab results. The goal is a patient-specific workflow for early diagnosis and effective treatment identification.
Researchers analyzed canine cell lines to understand cancer development and metastasis, identifying key gene switches that could be targeted with novel therapeutics. The study provides a basis for further research into personalized medicine for dogs with cancer.
The Beat AML collaboration has identified over 10 cell signaling pathways and mutations that may contribute to disease progression in acute myeloid leukemia. Researchers have also found promising therapeutic approaches, including disrupting the cancer cell microenvironment and targeting key inflammatory pathways.
A study published in The Lancet Oncology reveals that cancer drug prices vary significantly between European countries, with some nations paying up to 388% more than others for the same medication. The UK and Mediterranean countries have the lowest average unit manufacturer prices for a group of 31 originator cancer drugs, while German...
A new study published in Annals of Oncology shows that abiraterone acetate is effective in treating aggressive prostate cancers, even those with high Gleason scores. The treatment extended progression-free survival by up to 16.5 months in patients previously treated with docetaxel.